Second-line angiogenesis inhibition in metastatic colorectal cancer patients

Straightforward or overcrowded?

Riccardo Giampieri, Marta Caporale, Filippo Pietrantonio, Francesca V. Negri, Filippo De Braud, Francesco Giuliani, Valeria Pusceddu, Laura Demurtas, Angelo Restivo, Caterina Fontanella, Giuseppe Aprile, Stefano Cascinu, Mario Scartozzi

Research output: Contribution to journalArticle

Abstract

Although the number of therapeutic options targeting tumour angiogenesis is becoming increasingly relevant, the question of the optimal choice for second-line anti-angiogenic inhibition in combination with chemotherapy for metastatic colorectal cancer patients remains largely unanswered.In fact the lack of head to head comparison between consolidated options such as bevacizumab and new treatment alternatives such as aflibercept and ramucirumab makes the selection in the clinical practice challenging, particularly when the patient has already received an anti-angiogenic-based combination up-front.In the following pages we described the biological scenario validating second-line angiogenesis inhibition in colorectal cancer along with potential mechanism of resistance. We also critically described the available evidence recommending the use of the bevacizumab, aflibercept and ramucirumab in this setting with the final aim to guide the choice in the clinical practice.

Original languageEnglish
Pages (from-to)99-106
Number of pages8
JournalCritical Reviews in Oncology/Hematology
Volume100
DOIs
Publication statusPublished - Apr 1 2016

Fingerprint

Colorectal Neoplasms
Combination Drug Therapy
Therapeutics
Neoplasms
Bevacizumab
ramucirumab
aflibercept

Keywords

  • Aflibercept
  • Angiogenesis
  • Bevacizumab
  • Colorectal cancer
  • Ramucirumab
  • Second line

ASJC Scopus subject areas

  • Oncology
  • Hematology
  • Geriatrics and Gerontology

Cite this

Second-line angiogenesis inhibition in metastatic colorectal cancer patients : Straightforward or overcrowded? / Giampieri, Riccardo; Caporale, Marta; Pietrantonio, Filippo; Negri, Francesca V.; De Braud, Filippo; Giuliani, Francesco; Pusceddu, Valeria; Demurtas, Laura; Restivo, Angelo; Fontanella, Caterina; Aprile, Giuseppe; Cascinu, Stefano; Scartozzi, Mario.

In: Critical Reviews in Oncology/Hematology, Vol. 100, 01.04.2016, p. 99-106.

Research output: Contribution to journalArticle

Giampieri, R, Caporale, M, Pietrantonio, F, Negri, FV, De Braud, F, Giuliani, F, Pusceddu, V, Demurtas, L, Restivo, A, Fontanella, C, Aprile, G, Cascinu, S & Scartozzi, M 2016, 'Second-line angiogenesis inhibition in metastatic colorectal cancer patients: Straightforward or overcrowded?', Critical Reviews in Oncology/Hematology, vol. 100, pp. 99-106. https://doi.org/10.1016/j.critrevonc.2016.02.005
Giampieri, Riccardo ; Caporale, Marta ; Pietrantonio, Filippo ; Negri, Francesca V. ; De Braud, Filippo ; Giuliani, Francesco ; Pusceddu, Valeria ; Demurtas, Laura ; Restivo, Angelo ; Fontanella, Caterina ; Aprile, Giuseppe ; Cascinu, Stefano ; Scartozzi, Mario. / Second-line angiogenesis inhibition in metastatic colorectal cancer patients : Straightforward or overcrowded?. In: Critical Reviews in Oncology/Hematology. 2016 ; Vol. 100. pp. 99-106.
@article{f6aa471620ed425a8f935ca62a9f297e,
title = "Second-line angiogenesis inhibition in metastatic colorectal cancer patients: Straightforward or overcrowded?",
abstract = "Although the number of therapeutic options targeting tumour angiogenesis is becoming increasingly relevant, the question of the optimal choice for second-line anti-angiogenic inhibition in combination with chemotherapy for metastatic colorectal cancer patients remains largely unanswered.In fact the lack of head to head comparison between consolidated options such as bevacizumab and new treatment alternatives such as aflibercept and ramucirumab makes the selection in the clinical practice challenging, particularly when the patient has already received an anti-angiogenic-based combination up-front.In the following pages we described the biological scenario validating second-line angiogenesis inhibition in colorectal cancer along with potential mechanism of resistance. We also critically described the available evidence recommending the use of the bevacizumab, aflibercept and ramucirumab in this setting with the final aim to guide the choice in the clinical practice.",
keywords = "Aflibercept, Angiogenesis, Bevacizumab, Colorectal cancer, Ramucirumab, Second line",
author = "Riccardo Giampieri and Marta Caporale and Filippo Pietrantonio and Negri, {Francesca V.} and {De Braud}, Filippo and Francesco Giuliani and Valeria Pusceddu and Laura Demurtas and Angelo Restivo and Caterina Fontanella and Giuseppe Aprile and Stefano Cascinu and Mario Scartozzi",
year = "2016",
month = "4",
day = "1",
doi = "10.1016/j.critrevonc.2016.02.005",
language = "English",
volume = "100",
pages = "99--106",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Second-line angiogenesis inhibition in metastatic colorectal cancer patients

T2 - Straightforward or overcrowded?

AU - Giampieri, Riccardo

AU - Caporale, Marta

AU - Pietrantonio, Filippo

AU - Negri, Francesca V.

AU - De Braud, Filippo

AU - Giuliani, Francesco

AU - Pusceddu, Valeria

AU - Demurtas, Laura

AU - Restivo, Angelo

AU - Fontanella, Caterina

AU - Aprile, Giuseppe

AU - Cascinu, Stefano

AU - Scartozzi, Mario

PY - 2016/4/1

Y1 - 2016/4/1

N2 - Although the number of therapeutic options targeting tumour angiogenesis is becoming increasingly relevant, the question of the optimal choice for second-line anti-angiogenic inhibition in combination with chemotherapy for metastatic colorectal cancer patients remains largely unanswered.In fact the lack of head to head comparison between consolidated options such as bevacizumab and new treatment alternatives such as aflibercept and ramucirumab makes the selection in the clinical practice challenging, particularly when the patient has already received an anti-angiogenic-based combination up-front.In the following pages we described the biological scenario validating second-line angiogenesis inhibition in colorectal cancer along with potential mechanism of resistance. We also critically described the available evidence recommending the use of the bevacizumab, aflibercept and ramucirumab in this setting with the final aim to guide the choice in the clinical practice.

AB - Although the number of therapeutic options targeting tumour angiogenesis is becoming increasingly relevant, the question of the optimal choice for second-line anti-angiogenic inhibition in combination with chemotherapy for metastatic colorectal cancer patients remains largely unanswered.In fact the lack of head to head comparison between consolidated options such as bevacizumab and new treatment alternatives such as aflibercept and ramucirumab makes the selection in the clinical practice challenging, particularly when the patient has already received an anti-angiogenic-based combination up-front.In the following pages we described the biological scenario validating second-line angiogenesis inhibition in colorectal cancer along with potential mechanism of resistance. We also critically described the available evidence recommending the use of the bevacizumab, aflibercept and ramucirumab in this setting with the final aim to guide the choice in the clinical practice.

KW - Aflibercept

KW - Angiogenesis

KW - Bevacizumab

KW - Colorectal cancer

KW - Ramucirumab

KW - Second line

UR - http://www.scopus.com/inward/record.url?scp=84960452031&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960452031&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2016.02.005

DO - 10.1016/j.critrevonc.2016.02.005

M3 - Article

VL - 100

SP - 99

EP - 106

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

ER -